slc7a14a Antibody

What is SLC7A14 and how does it function in cellular metabolism?

SLC7A14 belongs to the solute carrier family 7 and functions as an amino acid transporter. Research has identified its significant role in the central nervous system, particularly in proopiomelanocortin (POMC) neurons where it regulates metabolic processes . Unlike some other SLC7 family members that show altered expression in cancer tissues, SLC7A14 has shown reduced expression in certain cancers compared to normal tissues .

From a mechanistic perspective, SLC7A14 has been shown to inhibit mTORC1 signaling through inhibition of TSC1 phosphorylation, placing it as an upstream regulator of this critical metabolic pathway . This relationship is particularly important when considering SLC7A14's role in aging-related metabolic changes.

What is the tissue distribution pattern of SLC7A14 expression?

SLC7A14 shows a distinctive tissue expression pattern that differs from other SLC7 family members. In the central nervous system, SLC7A14 is expressed in proopiomelanocortin (POMC) neurons within the hypothalamic arcuate nucleus (ARC) . Interestingly, SLC7A14 expression in these neurons decreases with age in mice, suggesting age-dependent regulation .

In breast tissue, SLC7A14 shows a contrasting pattern compared to some other SLC7 family members. While SLC7A1, SLC7A5, and SLC7A8 are significantly upregulated in breast cancer, SLC7A14 mRNA levels are lower in breast cancer tissues compared to normal tissues (P<0.01) . This downregulation pattern distinguishes SLC7A14 from several other SLC7 family members that show increased expression in cancer.

What validation methods should be employed when using SLC7A14 antibodies?

When working with SLC7A14 antibodies, comprehensive validation is essential to ensure specificity and reproducibility. Commercial antibodies like the polyclonal anti-SLC7A14 antibody are validated through multiple applications including immunohistochemistry (IHC), immunocytochemistry/immunofluorescence (ICC-IF), and Western blot (WB) . Researchers should perform their own validation studies that include:

• Positive and negative tissue controls: Compare tissues with known SLC7A14 expression (e.g., hypothalamic sections) with tissues where expression is minimal.

• Knockout/knockdown validation: Verify antibody specificity using SLC7A14 knockout or knockdown samples.

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining.

• Correlation with mRNA expression: Compare protein detection with RT-PCR results to confirm expression patterns.

These validation steps are particularly important given the research showing variable SLC7A14 expression across different tissues and pathological states .

What are the recommended experimental protocols for SLC7A14 detection in neural tissues?

For neural tissue detection of SLC7A14, particularly in hypothalamic sections containing POMC neurons, the following optimized protocol is recommended:

For immunohistochemistry (IHC):

• Fix brain tissue with 4% paraformaldehyde

• Embed in paraffin or prepare frozen sections (10-20 μm thickness)

• For paraffin sections, perform antigen retrieval (citrate buffer, pH 6.0)

• Block with 5% normal serum (matching secondary antibody host)

• Incubate with anti-SLC7A14 antibody (0.3 mg/ml, recommended dilution 1:100-1:500)

• Use fluorescent or HRP-conjugated secondary antibodies

• For co-localization studies, combine with neuronal markers like anti-POMC antibodies

For Western blot detection:

• Extract proteins using RIPA buffer with protease inhibitors

• Load 20-40 μg protein per lane

• Separate proteins on 8-10% SDS-PAGE gels (SLC7A14 molecular weight: ~75 kDa)

• Transfer to PVDF membranes

• Block with 5% non-fat milk

• Incubate with anti-SLC7A14 antibody (typical dilution 1:1000)

• Visualize using appropriate secondary antibody and detection system

Studies have successfully used these approaches to demonstrate age-dependent decreases in SLC7A14 expression in hypothalamic neurons .

How can SLC7A14 antibodies be applied to investigate aging-related metabolic changes?

SLC7A14 antibodies serve as valuable tools for investigating age-related metabolic changes, particularly in the context of lipolysis regulation. Research has demonstrated that SLC7A14 expression decreases in POMC neurons of aged mice, correlating with reduced lipolysis in white adipose tissue . When designing experiments to investigate this relationship, consider:

• Age-stratified experimental design: Compare SLC7A14 expression in hypothalamic sections from young (3-6 months) versus aged (18-24 months) mice using immunostaining with validated antibodies.

• Correlation analysis: Combine SLC7A14 immunostaining with metabolic parameters:

  • Phosphorylated hormone-sensitive lipase (HSL) levels in white adipose tissue

  • Glycerol release assays from adipose tissue explants

  • Body composition measurements

• Intervention studies: Use SLC7A14 antibodies to monitor expression changes after:

  • Viral-mediated overexpression of SLC7A14 in POMC neurons

  • Pharmacological interventions targeting the SLC7A14-regulated pathways

Research has shown that overexpression of SLC7A14 in POMC neurons alleviates aging-reduced lipolysis, while SLC7A14 deletion mimics age-induced lipolysis impairment . These findings highlight the utility of SLC7A14 antibodies in studying age-related metabolic dysregulation.

What insights can SLC7A14 antibodies provide regarding the brain-gut-adipose axis?

SLC7A14 antibodies are instrumental in elucidating the novel brain-gut-adipose tissue axis. Recent research has discovered that hypothalamic SLC7A14 regulates a complex signaling pathway involving intestinal bile acid transport and white adipose tissue lipolysis . When investigating this axis:

• Multi-tissue analysis: Use SLC7A14 antibodies to examine protein expression across:

  • Hypothalamic neurons (particularly POMC neurons)

  • Intestinal tissue (focusing on ileum)

  • White adipose tissue (subcutaneous and epididymal depots)

• Signaling pathway investigation: Combine SLC7A14 immunostaining with detection of:

  • Intestinal apical sodium-dependent bile acid transporter (ASBT)

  • PPARα expression in intestinal tissues

  • Phosphorylated hormone-sensitive lipase (HSL) in adipose tissue

Research has demonstrated that SLC7A14 in POMC neurons influences intestinal ASBT expression through a mechanism involving PPARα, ultimately affecting bile acid metabolism and adipose tissue lipolysis . This complex pathway represents a novel brain-gut-adipose crosstalk mechanism in which SLC7A14 antibodies play a critical detection role.

How does SLC7A14 interact with the mTORC1 signaling pathway?

SLC7A14 antibodies can be utilized to investigate the interaction between SLC7A14 and the mTORC1 signaling pathway. Research has established that SLC7A14 regulates intestinal sympathetic afferent nerves by inhibiting mTORC1 signaling through inhibition of TSC1 phosphorylation . To explore this interaction:

• Co-immunoprecipitation studies: Use SLC7A14 antibodies to:

  • Pull down SLC7A14 and probe for TSC1/TSC2 complex components

  • Examine physical interactions with mTORC1 components

• Phosphorylation analysis: Combine SLC7A14 detection with:

  • Phospho-TSC1 antibodies to assess inhibitory effects

  • Phospho-S6K and phospho-4EBP1 antibodies to measure downstream mTORC1 activity

• Pharmacological interventions: Use SLC7A14 antibodies to monitor expression following:

  • mTORC1 inhibitors (rapamycin, rapalogs)

  • Activators of the pathway (amino acids, growth factors)

Understanding this regulatory relationship provides insight into how SLC7A14 functions as an upstream regulator of mTORC1 signaling, with implications for metabolic regulation and aging .

What are common challenges when detecting SLC7A14 in different experimental systems?

Researchers face several technical challenges when detecting SLC7A14:

• Low endogenous expression: SLC7A14 may be expressed at low levels in certain tissues, necessitating:

  • Signal amplification techniques (TSA amplification for IHC)

  • Extended primary antibody incubation times (overnight at 4°C)

  • Increased antibody concentrations for Western blotting

• Specificity concerns: The SLC7 family contains multiple members with potential sequence homology:

  • Always include appropriate negative controls

  • Consider parallel detection of mRNA using qPCR or in situ hybridization

  • Verify band specificity in Western blots with positive and negative controls

• Age-dependent expression: As SLC7A14 expression decreases with age in certain tissues , consider:

  • Age-matching experimental animals

  • Using sufficiently sensitive detection methods for aged samples

  • Including positive controls from younger animals

• Antibody selection: When choosing between polyclonal and monoclonal antibodies:

  • Polyclonal antibodies may provide higher sensitivity for low-abundance targets

  • Monoclonal antibodies offer greater specificity but potentially lower sensitivity

  • Consider epitope accessibility in your experimental system

What genetic approaches can be combined with antibody detection for SLC7A14 research?

Integrating genetic approaches with antibody detection provides powerful insights into SLC7A14 function:

• Conditional knockout strategies: Several approaches have proven effective:

  • Floxed SLC7A14 mice crossed with tissue-specific Cre lines

  • AAV-Cre delivery for region-specific deletion

  • CRISPR/Cas9-mediated deletion in cell culture models

• Overexpression models: Researchers have successfully employed:

  • AAV-mediated overexpression in specific brain regions

  • Conditional transgenic approaches

  • Lentiviral delivery systems for cellular models

• Validation protocols: When using genetic models, validate with:

  • SLC7A14 antibody staining to confirm protein loss/increase

  • RT-PCR to verify transcript changes

  • Functional assays (e.g., glycerol release for lipolysis studies)

Research has shown that knockdown of SLC7A14 in the hypothalamic arcuate nucleus (ARC) increased body fat mass without changing body weight, mimicking age-induced reduction in WAT lipolysis . Similarly, overexpression of SLC7A14 in POMC neurons alleviated aging-reduced lipolysis, demonstrating the utility of combining genetic approaches with antibody detection.

What experimental controls are essential when studying SLC7A14 in disease models?

When investigating SLC7A14 in disease contexts, rigorous controls are essential:

• Age-matched controls: Particularly important given the age-dependent regulation of SLC7A14 :

  • Use animals of identical age for experimental and control groups

  • Consider additional controls representing different age points if studying age-progressive conditions

• Antibody validation controls:

  • Include SLC7A14 knockout/knockdown tissues as negative controls

  • Use peptide competition assays to confirm staining specificity

  • Employ isotype control antibodies to assess non-specific binding

• Physiological controls:

  • Monitor metabolic parameters (body weight, fat mass, food intake)

  • Assess tissue-specific markers (e.g., phosphorylated HSL for lipolysis)

  • Include additional SLC7 family members as comparators

• Cellular controls for co-localization studies:

  • Include markers for specific cell types (e.g., POMC neurons)

  • Perform parallel studies with other transporters or channel proteins

  • Assess subcellular localization with organelle markers

Research examining SLC7A14's role in aging-related metabolic changes employed extensive controls, including food intake monitoring, body weight tracking, and analysis of multiple adipose depots to distinguish specific effects from general metabolic alterations .

How might SLC7A14 antibodies contribute to understanding neurodegenerative diseases?

Given SLC7A14's expression in neural tissues and its age-dependent regulation, antibodies against this transporter could advance understanding of neurodegenerative diseases:

• Expression profiling: SLC7A14 antibodies could be used to:

  • Compare expression patterns in post-mortem brain tissues from neurodegenerative disease patients versus controls

  • Examine age-related changes in expression across brain regions affected by neurodegeneration

  • Investigate correlations between SLC7A14 levels and disease severity markers

• Mechanistic investigations: Building on SLC7A14's known interaction with mTORC1 signaling :

  • Explore altered mTORC1 activity in neurodegenerative conditions in relation to SLC7A14 expression

  • Investigate potential neuroprotective effects of SLC7A14 overexpression

  • Examine how SLC7A14-regulated metabolic pathways influence neuronal health

• Therapeutic development: SLC7A14 antibodies could facilitate:

  • Screening compounds that modulate SLC7A14 expression or function

  • Validating target engagement in preclinical studies

  • Monitoring treatment effects on SLC7A14-regulated pathways

Current literature suggests connections between SLC7A14, aging, and metabolic regulation that may have significant implications for age-related neurodegenerative processes .

What is known about post-translational modifications of SLC7A14 and how can they be detected?

Post-translational modifications (PTMs) of SLC7A14 represent an emerging area of research where specialized antibodies can provide crucial insights:

• Phosphorylation: While specific phosphorylation sites on SLC7A14 are not well-characterized in the provided literature, research on related SLC7 family members suggests potential regulatory phosphorylation:

  • Phospho-specific antibodies could be developed against predicted sites

  • Mass spectrometry approaches combined with immunoprecipitation using SLC7A14 antibodies could identify novel modification sites

  • Treatment with phosphatase inhibitors may enhance detection of phosphorylated forms

• Ubiquitination and protein stability: The relationship between SLC7A14 and protein degradation pathways remains to be explored:

  • Co-immunoprecipitation with ubiquitin antibodies following SLC7A14 pull-down

  • Proteasome inhibitor treatments to assess regulation of protein levels

  • Cycloheximide chase experiments using SLC7A14 antibodies to measure protein half-life

• Glycosylation: As a membrane protein, SLC7A14 may undergo N-linked glycosylation:

  • Enzymatic deglycosylation followed by Western blotting to assess mobility shifts

  • Lectin affinity approaches combined with SLC7A14 immunodetection

  • Site-directed mutagenesis of predicted glycosylation sites with subsequent antibody detection

The field of SLC7A14 post-translational modifications represents an important frontier for future research that will benefit from the development and application of modification-specific antibodies.